Telomelysin

Drug Profile

Telomelysin

Alternative Names: hTERT-Ad; OBP-301; Telomelysin

Latest Information Update: 17 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncolys Biopharma
  • Developer Okayama University; Oncolys BioPharma
  • Class Antineoplastics; Oncolytic viruses; Viral proteins
  • Mechanism of Action Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Head and neck cancer; Hepatocellular carcinoma; Non-small cell lung cancer; Oesophageal cancer
  • Preclinical Adenocarcinoma; Neuroblastoma
  • No development reported Breast cancer; Mesothelioma; Osteosarcoma; Skin cancer; Soft tissue sarcoma

Most Recent Events

  • 07 Jul 2017 Oncolys BioPharma enrols the first patient in a phase I trial for Oesophageal cancer in Japan
  • 29 Jun 2017 Oncolys BioPharma submits a clinical trial notification (CTN) with the Pharmaceuticals and Medical Devices Agency (PMDA) for Solid tumours in Japan
  • 27 Jun 2017 Oncolys initiates enrolment in a phase I trial for Oesophageal cancer in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top